HLS vs. CRDL, CPH, CWEB, LABS, OGI, ONC, EDT, SVA, TH, and MDNA
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Cardiol Therapeutics (CRDL), Cipher Pharmaceuticals (CPH), Charlotte's Web (CWEB), MediPharm Labs (LABS), Organigram (OGI), Oncolytics Biotech (ONC), Spectral Medical (EDT), Sernova (SVA), Theratechnologies (TH), and Medicenna Therapeutics (MDNA). These companies are all part of the "medical" sector.
HLS Therapeutics (TSE:HLS) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
HLS Therapeutics presently has a consensus price target of C$3.88, indicating a potential downside of 0.13%. Given HLS Therapeutics' higher probable upside, equities analysts plainly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.
HLS Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
In the previous week, HLS Therapeutics' average media sentiment score of 0.92 beat Cardiol Therapeutics' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.
HLS Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics has a net margin of 0.00% compared to HLS Therapeutics' net margin of -45.81%. HLS Therapeutics' return on equity of -26.78% beat Cardiol Therapeutics' return on equity.
59.7% of HLS Therapeutics shares are held by institutional investors. Comparatively, 13.0% of Cardiol Therapeutics shares are held by institutional investors. 0.5% of HLS Therapeutics shares are held by insiders. Comparatively, 4.4% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
HLS Therapeutics received 25 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 68.00% of users gave HLS Therapeutics an outperform vote.
Summary
HLS Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
